Viewing nowCombinationSitafolmin 50/850 mg Tablet
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.

MFDS item code 201503513 · Approved 2015.05.29 · Insurance code 643307070
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist blood sugar control in patients with type 2 diabetes, in conjunction with dietary and exercise therapy. The combination of sitagliptin and metformin effectively manages blood glucose levels to aid in diabetes treatment.
For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) together with their current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. When adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medicine. Since any change in treatment for type 2 diabetes may cause changes in glycemic control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin and is used for diabetes treatment. Severe allergic reactions may occur when taking this medication; if symptoms such as rash, difficulty breathing, or swelling of the face or neck develop, discontinue use immediately and consult a physician. Inflammation of the pancreas, known as acute pancreatitis, may occur; if severe abdominal pain, nausea, or vomiting symptoms appear, visit a hospital immediately. Patients with poor kidney function, dehydration, severe infections, or cardiovascular issues should not use this medication. Particularly, it is essential to stop taking this medication before tests involving iodinated contrast agents and confirm normal kidney function. It is safer for women who are pregnant or potentially pregnant, as well as nursing mothers, to avoid this medication. This medication may cause hypoglycemia, so caution should be exercised when skipping meals, having irregular eating patterns, or engaging in strenuous exercise. The risk of hypoglycemia may increase when taken with other blood glucose-lowering medications, necessitating dosage adjustments under medical guidance. Regular monitoring of kidney function and blood vitamin B12 levels is required during treatment, and caution is necessary for patients with impaired liver function. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment. For patients undergoing surgery, medication should be discontinued 48 hours before the procedure and resumed only after kidney function has returned to normal. This medication can cause gastrointestinal disorders, diarrhea, headaches, or upper respiratory infections; if severe joint pain or blistering symptoms occur, inform a doctor immediately. In cases of overdose, general symptomatic treatment along with blood dialysis may be necessary to eliminate the drug. While taking this medication, regular checks of blood sugar, kidney function, liver function, and blood tests should be performed according to the doctor's instructions.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, joint pain with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dermatitis, loss of appetite, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the drug's efficacy over time.
Pink oval film-coated tablet
PTP - 30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.